rilmenidine
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
2
Earliest trial started Nov 1, 2009 (NCT00892892)
Timeline
No events for the selected filters.
Indications
Approved for
Mechanism of action
- NischarinAGONIST
Nischarin agonist
- Unspecified targetINHIBITOR
inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C1COC(NC(C2CC2)C2CC2)=N1- Mol. weight
- 180.25 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL289480 ↗
Also known as
- 2-(n-(dicyclopropylmethyl)amino)oxazoline
- 2-(n-(dicyclopropylmethyl)amino)oxazoline phosphate salt
- 2-oxazolamine, n-(dicyclopropylmethyl)-4,5-dihydro-
- hyperium
- hyperium
- hyperium
- oxaminozoline
- oxaminozoline
- rilmenidene
- rilmenidine
- rilmenidine
- rilmenidine
- rilmenidine
- rilmenidine
- rilmenidine
- rilmenidine
- rilmenidine
- rilmenidine dihydrogen phosphate
- rilmenidine phosphate
- rilmenidine phosphate
- s3341
- s 3341
- s-3341
- s-3341-3
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02539810 | Phase 4 | Sep 1, 2015 | Government of France, University of Paris |
| NCT00892892 | Phase 4 | Nov 1, 2009 | University of Erlangen-Nuremberg |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of France | Government | 1 | 0 | 1 | 2015 |
| University of Erlangen-Nuremberg | Academic/Hospital | 1 | 1 | 1 | 2009 |
| University of Paris | Academic/Hospital | 1 | 1 | 1 | 2015 |
3 organizations
Page 1 / 1